Evidence map›Paper›PMID 39906736›Full record

Observational studyFrontiers in immunology2024

Humoral and cell-mediated immune responses to COVID-19 vaccines up to 6 months post three-dose primary series in adults with inborn errors of immunity and their breakthrough infections.

Dana Unninayar, Emilia L Falcone, Hugo Chapdelaine, Donald C Vinh, Karina A Top, Beata Derfalvi, Thomas B Issekutz, Hélène Decaluwe, Anne Pham-Huy, Julia Upton and 15 more

Abstract readMulticenter StudyObservational Study
PubMed Full text at PMC Publisher
In one paragraph

Observational study in Frontiers in immunology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Observational
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

25 authors.

Dana UnninayarInflammation and Chronic Disease Program, The Ottawa Hospital Research Institute, Ottawa, ON, Canada.
Emilia L FalconeDepartment of Medicine, Centre Hospitalier de l'Université de Montréal, Montreal, QC, Canada.
Hugo ChapdelaineDepartment of Medicine, Centre Hospitalier de l'Université de Montréal, Montreal, QC, Canada.
Donald C VinhDepartment of Medicine, McGill University Health Centre, Montreal, QC, Canada.
Karina A TopIWK Health, Department of Pediatrics, Dalhousie University, Halifax, NS, Canada.
Beata DerfalviIWK Health, Department of Pediatrics, Dalhousie University, Halifax, NS, Canada.
Thomas B IssekutzIWK Health, Department of Pediatrics, Dalhousie University, Halifax, NS, Canada.
Hélène DecaluweCentre Hospitalier de l'Université (CHU) Ste Justine, Centre de Recherche, Montreal, QC, Canada.
Anne Pham-HuyDepartment of Pediatrics, Children's Hospital of Eastern Ontario, Ottawa, ON, Canada.
Julia UptonThe Hospital for Sick Children, Department of Pediatrics, University of Toronto, Toronto, ON, Canada.
Stephen D BetschelClinical Immunology and Allergy, Unity Health Toronto, Toronto, ON, Canada.
Tamar RubinDepartment of Pediatrics and Child Health, University of Manitoba, Winnipeg, MB, Canada.
Sneha SureshDepartment of Pediatrics, University of Alberta, Edmonton, AB, Canada.
Nicola A M WrightAlberta Children's Hospital, Calgary, AB, Canada.
Luis Murguía-FavelaAlberta Children's Hospital, Calgary, AB, Canada.
Tatiana KalashnikovaAlberta Children's Hospital, Calgary, AB, Canada.
Lisa BarrettDepartment of Medicine, Dalhousie University, Halifax, NS, Canada.
Sharon OldfordDepartment of Medicine, Dalhousie University, Halifax, NS, Canada.
Marc-Andre LangloisDepartment of Biochemistry, Microbiology, and Immunology, University of Ottawa, Ottawa, ON, Canada.
Corey ArnoldDepartment of Biochemistry, Microbiology, and Immunology, University of Ottawa, Ottawa, ON, Canada.
Manish SadaranganiDepartment of Pediatrics, University of British Columbia, Vancouver, BC, Canada.
Tinghua ZhangInflammation and Chronic Disease Program, The Ottawa Hospital Research Institute, Ottawa, ON, Canada.
Tim RamsayInflammation and Chronic Disease Program, The Ottawa Hospital Research Institute, Ottawa, ON, Canada.
Dina YazjiDepartment of Biochemistry, Microbiology, and Immunology, University of Ottawa, Ottawa, ON, Canada.
Juthaporn CowanInflammation and Chronic Disease Program, The Ottawa Hospital Research Institute, Ottawa, ON, Canada.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Purpose: Many individuals with inborn errors of immunity (IEIs) have poor humoral immune (HI) vaccine responses. Only a few studies have examined specific cell-mediated immune (CMI) responses to coronavirus disease 2019 (COVID-19) vaccines in this population. Therefore, the purpose of this study was to examine HI and CMI responses up to 6 months post-COVID-19 vaccine dose 3 in adults with IEIs. Methods: A multi-center prospective observational study was conducted across Canada to collect severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2)-specific HI and CMI data at 4- and 24-week intervals after vaccine doses 2 and 3 (D2 + 4wk/D2 + 24wk/D3 + 4wk/D3 + 24wk). Results: A total of 149 adults with IEIs and 423 healthy controls were recruited from July 2021 to October 2023. Geometric mean anti-spike IgG (binding antibody units/mL) and spike-specific T-cell responses [IFN-γ Conclusion: Adults with IEIs mounted both HI and CMI responses following COVID-19 vaccines, which were lower than those of healthy individuals but were present at least up to 6 months after dose 3. These data support the initial recommendation for a three-dose primary series among IEIs.

Indexed as

COVID-19COVID-19 VaccinesImmunity, CellularImmunity, HumoralSARS-CoV-2AdultAgedAntibodies, ViralBreakthrough InfectionsCanadaFemaleHumansImmunoglobulin GMaleMiddle AgedProspective StudiesAntibodies, ViralCOVID-19 VaccinesImmunoglobulin GSpike Glycoprotein, Coronaviruscellular mediated immunityCOVID-19humoral immunityimmunogenicityinborn error of immunityvaccine response

Identifiers

PMID39906736
PMCPMC11790575

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.